Drug Trial Radar · NCT06615050
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
572
Planned (sponsor's estimate)
Start
Apr 2, 2025
Primary completion
Jan 17, 2031
Study completion Jan 17, 2031
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- Blood and Marrow Transplant Clinical Trials Network; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI)
- First posted
- Sep 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Conditions
- Graft-versus-host Disease (GVHD)
Interventions
Tacrolimus (Tac)Drug
Tablet or intravenously (IV)
Methotrexate (MTX)Drug
Intravenously (IV)
Ruxolitinib (Rux)Drug
Tablet
CyclophosphamideDrug
Intravenously (IV)
Mycophenolate mofetil (MMF)Drug
Tablet or intravenously (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- GVHD-free survival (GFS)Time frame: Up to 24 months post-transplant (Day 0)
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Stanford Cancer Center
Palo Alto, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
University of Miami
Miami, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia · Recruiting
Indiana University Cancer Center
Indianapolis, Indiana · Recruiting
University of Kansas Hospital Authority
Kansas City, Kansas · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
Washington University
St Louis, Missouri · Recruiting
Mount Sinai Hospital
New York, New York · Recruiting
Memorial Sloan Kettering
New York, New York · Recruiting
University of North Carolina At Chapel Hill
Chapel Hill, North Carolina · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
Sarah Cannon
Nashville, Tennessee · Recruiting
Vanderbilt Medical Center
Nashville, Tennessee · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
Virginia Commonwealth University, North Hospital
Richmond, Virginia · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
University of Wisconsin
Madison, Wisconsin · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.